Drug Trial Radar · NCT04316442
Study of the Safety and Efficacy of STI-6129 in Patients With Relapsed or Refractory Systemic AL Amyloidosis
Last checked: Nov 19, 2026Latest source record: Jan 17, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
60
Planned (sponsor's estimate)
Start
Apr 1, 2021
Primary completion
Sep 2024
Study completion Dec 2024
Sponsor
- Lead sponsor
- Sorrento Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 20, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The STI-6129-001 study is a three-stage, multicenter, open-label, dose-finding, phase 1b/2a trial. It is designed primarily to identify the recommended phase 2 dose (RP2D) of STI-6129 by assessing the safety, preliminary efficacy and pharmacokinetics of this anti-CD38-Duostatin 5.2 antibody-drug conjugate (ADC) for the treatment of relapsed or refractory systemic AL amyloidosis. The patients that will be treated with STI-6129 in this trial are relapsed or refractory systemic AL amyloidosis patients who have received prior lines of treatment.
Conditions
- Light Chain (AL) Amyloidosis
Interventions
STI-6129Biological
Four cycles of intravenous infusion of STI-6129 will be given (one infusion every four weeks).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability of STI-6129 in AL amyloidosis patientsTime frame: Baseline through study completion at up to 14 months
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
City of Hope National Medical Center
Duarte, California · Recruiting
Boston Medical Center
Boston, Massachusetts · Recruiting
Barbara Ann Karmanos Cancer Institute Wertz Clinic
Detroit, Michigan · Recruiting
Froedtert Hospital & the Medical College of Wisconsin
Milwaukee, Wisconsin · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.